METTL1 and hepatocellular carcinoma: Functional experiments demonstrated that METTL1 knockdown suppresses HCC cell proliferation and promotes apoptosis under lenvatinib treatment, thereby overcoming resistance, whereas overexpression of wild-type METTL1 (but not catalytic-dead mutants) induces drug resistance (7).